Top Markets
#1 ADO Protocol ADO Protocol +335.27%
#2 Islamic Coin Islamic Coin +155.40%
#3 GoPlus Security GoPlus Security +45.02%
#4 Starpower Starpower +35.19%
#5 GAIB AID GAIB AID +24.67%
#6 Casper Network Casper Network +14.74%
#7 Nockchain Nockchain +12.81%
#8 Power Protocol Power Protocol +11.88%
#9 o1.exchange o1.exchange +11.28%
#10 Status Status +10.86%
Coin of the day
ADO Protocol ADO Protocol
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
CNS Pharmaceuticals, Inc. CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc.

CNSP
Classement en actions #33273
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily... CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Prix de l'action
$5.47
Dernière synchronisation: 2026-08-14
Capitalisation boursière
$7.99M
Changement (1 jour)
6.21%
Changement (1 an)
7.47%
Pays
US
Échange CNS Pharmaceuticals, Inc. (CNSP)

Catégorie

Healthcare
Bénéfices pour CNS Pharmaceuticals, Inc. (CNSP)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de CNS Pharmaceuticals, Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour CNS Pharmaceuticals, Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE